Cytokinetics Inc. Stock
Price
Target price
€56.04
€56.04
-1.590%
-0.9
-1.590%
€71.95
23.04.26 / Tradegate
WKN: A1W1KK / Symbol: CYTK / Name: Cytokinetics / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Cytokinetics Inc. Stock
We can see a decrease in the price for Cytokinetics Inc.. Compared to yesterday it has lost -€0.900 (-1.590%).
With 40 Buy predictions and not a single Sell prediction Cytokinetics Inc. is an absolute favorite of our community.
With a target price of 71 € there is a positive potential of 26.7% for Cytokinetics Inc. compared to the current price of 56.04 €.
So far the community has only identified positive things for Cytokinetics Inc. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Cytokinetics Inc. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
M***** P*******
?
C******** o* t** e**********
Cons
?
B****
?
S********** s********
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Cytokinetics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Cytokinetics Inc. | -1.590% | 1.009% | 6.743% | 66.786% | 4.748% | 67.784% | 154.727% |
| Sangamo Therapeutics Inc. | -29.780% | -28.034% | -47.326% | -77.235% | -53.545% | -89.092% | -98.322% |
| Evolus Inc | -0.620% | 13.182% | 16.719% | -56.059% | -17.761% | -42.168% | -41.792% |
| Corbus Pharmaceuticals Holding Inc. | -2.290% | 1.805% | 20.552% | 34.462% | 24.857% | 6696.267% | -79.570% |
Comments
Cytokinetics (CYTK) is now covered by Wells Fargo & Company. They set an "overweight" rating and a $95.00 price target on the stock.
Show more
Ratings data for CYTK provided by MarketBeat
Cytokinetics (CYTK) had its price target raised by Barclays PLC from $87.00 to $95.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for CYTK provided by MarketBeat
Cytokinetics (CYTK) had its price target raised by Mizuho from $84.00 to $100.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for CYTK provided by MarketBeat
News
Cytokinetics Insider Exercises Options Worth Over $920,000 as Heart Drug Hits the Market
On Feb. 5, 2026, Andrew Callos, Executive Vice President and Chief Commercial Officer of Cytokinetics (NASDAQ:CYTK), exercised 15,000 options for common stock and immediately sold the resulting
This Cytokinetics Director Sold 5,000 Shares in November. Is It Time to Dump the Biopharmaceutical Stock?
B. Lynne Parshall, Director at Cytokinetics, Incorporated (NASDAQ:CYTK), reported the sale of 5,000 shares in an open-market transaction valued at ~$323,650 on November 19, 2025; direct ownership
Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares
Foresite Capital Management IV, LLC disclosed a new stake in Cytokinetics (NASDAQ:CYTK), adding 458,295 shares valued at $25.19 million as of Sept. 30, 2025. The move was detailed in a quarterly